T Cell Therapy for Re-Sensitizing Cancer to Prior Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer cells develop resistance to prior therapies, leading to relapse or refractoriness, necessitating improved strategies to re-sensitize them for effective treatment.
Innovation Solution
Administering a T cell therapy, such as CAR T cells or TCEs, followed by a subsequent therapy of the same class, to subjects who have relapsed or are refractory, with the T cell therapy altering high-risk tumor features and achieving minimum residual disease negative status, thereby re-sensitizing the cancer to the subsequent therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a prior therapy is administered to treat cancer, then cancer cells are initially controlled, but cancer cells develop resistance leading to relapse or refractoriness
Solution Approach 1:
The patent applies preliminary action by administering a T cell therapy before the cancer relapses or becomes refractory to prior therapy. The T cell therapy is given at a specific time window when the cancer is still sensitive, to prevent the development of resistance and maintain long-term control, thereby extending the duration of treatment effectiveness.
Solution Approach 2:
The T cell therapy acts as an intermediary between the prior therapy and the cancer cells. It modifies the tumor microenvironment and alters high-risk tumor features, making the cancer cells susceptible to subsequent prior therapy administration. This intermediary action resolves the contradiction by enabling re-sensitization after resistance develops.
2Reliability
If a T cell therapy is administered to achieve MRD negative status, then cancer cells are controlled, but the treatment sequence and timing become complex
Solution Approach 1:
The treatment protocol is segmented into distinct phases: (1) administration of prior therapy to achieve initial control, (2) administration of T cell therapy at relapse or refractoriness to achieve MRD negative status, and (3) re-administration of prior therapy to consolidate response. This segmentation clarifies the complex treatment sequence and makes it manageable.
Solution Approach 2:
The treatment sequence is dynamic rather than static. The timing and selection of therapies are adjusted based on the cancer's response status, MRD levels, and emergence of resistance. This dynamic approach optimizes effectiveness while managing complexity through adaptive decision-making.
3Adaptability or versatility
If cancer cells develop resistance mutations, then they survive prior therapy, but the cancer becomes refractory to subsequent treatment
Solution Approach 1:
The patent converts the harm of resistance development into a benefit by using the T cell therapy to selectively eliminate resistant clones and alter tumor features. The resistance mutations that allow survival under prior therapy pressure become targets for T cell-mediated elimination, transforming the survival advantage into a vulnerability that can be exploited for improved subsequent treatment response.
Data Source
AI summary
Provided herein are methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a T cell therapy.